Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18741683 | Compositions And Methods Of BDNF Activation | June 2024 | January 2026 | Allow | 19 | 2 | 0 | No | No |
| 18361787 | METHODS AND COMPOSITIONS FOR FREEZING AND THAWING MAMMALIAN CELLS | July 2023 | January 2026 | Allow | 30 | 5 | 1 | Yes | No |
| 18161046 | MATERIALS AND METHODS FOR IMPROVING IMMUNE RESPONSES AND SKIN AND/OR MUCOSAL BARRIER FUNCTIONS | January 2023 | August 2025 | Allow | 31 | 1 | 1 | Yes | No |
| 18002224 | APTAMERS AGAINST SARS-COV-2 | December 2022 | March 2026 | Abandon | 39 | 0 | 1 | No | No |
| 17791856 | SELF-ASSEMBLING, SELF-ADJUVANTING SYSTEM FOR DELIVERY OF VACCINES | July 2022 | January 2026 | Abandon | 43 | 0 | 1 | No | No |
| 17834573 | Compositions and Methods for Inducing an Immune Response | June 2022 | January 2026 | Abandon | 44 | 0 | 1 | Yes | No |
| 17772651 | IMPROVED METHOD FOR MANUFACTURING ALLULOSE | April 2022 | January 2026 | Allow | 45 | 2 | 1 | No | No |
| 17770521 | NOVEL CORONAVIRUS VACCINE BASED ON INFLUENZA VIRUS VECTOR AND PREPARATION METHOD THEREOF | April 2022 | December 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17724722 | SIZE-BASED DETECTION AND QUANTIFICATION OF FUNCTIONAL BIO-NANOPARTICLES | April 2022 | December 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17769684 | SARS-COV-2 RECOMBINANT RBD PROTEIN, AND PREPARATION METHOD THEREFOR | April 2022 | January 2026 | Abandon | 45 | 2 | 0 | No | No |
| 17767280 | COMPOSITIONS AND METHODS FOR MEASURING AND INHIBITING CALPAIN-5 ACTIVITY | April 2022 | August 2025 | Allow | 40 | 2 | 1 | No | No |
| 17766705 | Antibodies against infectious pathogens and method for production thereof | April 2022 | January 2026 | Allow | 46 | 1 | 1 | No | No |
| 17685756 | ASSAY FOR PROGNOSIS OF COVID-19 DISEASE | March 2022 | November 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17675418 | METHOD FOR ASSISTING DETERMINATION OF EXACERBATION RISK OF COVID-19 | February 2022 | November 2025 | Abandon | 45 | 1 | 0 | No | No |
| 17618193 | ADENO ASSOCIATED VIRAL VECTOR DELIVERY OF ANTIBODIES FOR THE TREATMENT OF DISEASE MEDIATED BY DYSREGULATED PLASMA KALLIKREIN | December 2021 | October 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17522648 | METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH gp120 CD4 BINDING SITE-DIRECTED ANTIBODIES | November 2021 | October 2025 | Allow | 47 | 2 | 1 | Yes | No |
| 17381930 | Method to Produce Virus in Cultured Cells Supplemented With Alpha-Ketoglutarate | July 2021 | November 2025 | Abandon | 52 | 3 | 0 | No | No |
| 17230821 | Methods for the Treatment of Solid Tumor Cancers Using Illudins and Biomarkers | April 2021 | May 2025 | Abandon | 49 | 2 | 1 | No | No |
| 16959634 | Topical Skin Care Compositions | July 2020 | January 2026 | Allow | 60 | 6 | 1 | No | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner VISONE, THOMAS J works in Art Unit 1672 and has examined 5 patent applications in our dataset. With an allowance rate of 40.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 49 months.
Examiner VISONE, THOMAS J's allowance rate of 40.0% places them in the 7% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by VISONE, THOMAS J receive 2.60 office actions before reaching final disposition. This places the examiner in the 76% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by VISONE, THOMAS J is 49 months. This places the examiner in the 6% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +75.0% benefit to allowance rate for applications examined by VISONE, THOMAS J. This interview benefit is in the 99% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 12.5% of applications are subsequently allowed. This success rate is in the 7% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 33.3% of cases where such amendments are filed. This entry rate is in the 49% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants file petitions regarding this examiner's actions, 200.0% are granted (fully or in part). This grant rate is in the 98% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 3% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 3% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.